From the company’s inception, GeneMind aimed at the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostics. Genemind is committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions.
Background: The base composition of Whole Genome Bisulfite Sequencing (WGBS) libraries exhibits a severe imbalance (GC content of approximately 20%), posing significant challenges for delivering high-quality WGBS sequencing data. Conventionally,
Human exonic regions account for only 1-2% of the whole genome, yet they contain about 85% of disease-causing mutations. Whole exome sequencing (WES) can significantly improve the detection rate of
On October 15, 2024, GeneMind hosted the “2024 Life Omics Innovation Ecosystem Conference and GeneMind New Product Launch” in Nanjing, Jiangsu province. With the theme “Sequencing Powerhouse: Unlocking the Genetic Potential”, the event
*Unless otherwise informed, GeneMind sequencing platform and related sequencing reagents are not available in the USA, Canada, Australia, Japan, Singapore, Western Europe and Nordic countries yet.
